$ADGM News

LUCID CAPITAL MARKETS Initiates Coverage On Adagio Medical Holdings with Buy Rating, Announces Price Target of $3

Adagio Medical Submits PMA Application To FDA For vCLAS Ventricular Ablation System For Treatment Of Drug-Refractory, Recurrent, Sustained Monomorphic VT In Patients With Ischemic Or Non-Ischemic Structural Heart Disease

Adagio Medical Reports First Quarter 2026 Results and Meaningful Clinical Progress

Adagio Medical Holdings Q1 EPS $(0.31) Misses $(0.29) Estimate

Adagio Medical to Participate in the BofA Securities 2026 Health Care Conference

Adagio Medical Holdings shares are trading lower. The company presented six-month results from its FULCRUM-VT Investigational Device Exemption clinical trial.

Adagio Medical Holdings shares are trading lower. The company presented six-month results from its FULCRUM-VT Investigational Device Exemption clinical trial.

Adagio Medical Heart Ablation System Shows 84% Freedom From Shock

Reported Sunday, Adagio Medical's FULCRUM-VT Pivotal IDE Trial Meets Safety And Effectiveness Endpoints With 84% Freedom From Shock And 59% Freedom From VT Recurrence

Adagio Medical Announces Positive Pivotal Results for vCLAS® Ventricular Ablation System

Adagio Medical’s ULTA Technology to Be Featured at the Heart Rhythm 2026 Conference

Adagio Medical Holdings shares are trading higher after Piper Sandler initiated coverage on the stock with an Overweight rating and announced a $3 price target.

Piper Sandler Initiates Coverage On Adagio Medical Holdings with Overweight Rating, Announces Price Target of $3

Adagio Medical Receives IDE Approval from the FDA to Investigate Next-Generation vCLAS® Ventricular Ablation System

Adagio Medical's FULCRUM-VT Trial Receives FDA's Investigational Device Exemption Approval To Evaluate Safety, Effectiveness Of vCLAS Ultra-Low Temperature Ablation Ventricular Ablation System To Treat Sustained Monomorphic Ventricular Tachycardia

Adagio Medical to Participate in the 25th Annual Needham Virtual Conference

Adagio Medical Ultralow Temperature Ablation U.S. Pivotal Study Results to be Presented in Late-Breaking Session at Heart Rhythm Society 2026

Adagio Medical Reports Fourth Quarter and Full Year 2025 Results

Adagio Medical Holdings Q4 EPS $(0.21) Beats $(0.31) Estimate

Adagio Medical Announces Publication of Pre-Clinical Results for Next Generation Ventricular Ablation Catheter